Search

Displaying results 4041 - 4050 of 5261 in total
  1. Drug

    BB 21217

    go.drugbank.com/drugs/DB17373
    Investigational

    BB 21217 is an anti-BCMA CAR T cell therapy that uses the same CAR molecule as [idecabtagene vicleucel] (bb2121), but adds the PI3K inhibitor bb007 during ex vivo culture to enrich the drug product (DP

  2. Drug

    TTAX01

    go.drugbank.com/drugs/DB17928
    Investigational

    TTAX01 is a cryopreserved human umbilical cord product being developed by TissueTech.[L47246]

  3. Drug

    Homocysteine

    go.drugbank.com/drugs/DB04422
    Investigational

    Homocysteine is a thiol-containing amino acid formed by a demethylation of methionine.

  4. Drug

    Diethyltryptamine

    go.drugbank.com/drugs/DB01460
    ExperimentalIllicit

    Diethyltryptamine (DET) is an orally active hallucinogenic agent and a substituted form of tryptamine.

    Synonyms: N,N-Diethyltryptamine
  5. Drug

    alpha-D-quinovopyranose

    go.drugbank.com/drugs/DB03773
    Experimental

    The pyranose form of D-quinovose with an α-configuration at the anomeric position .

  6. Drug

    Metrizamide

    go.drugbank.com/drugs/DB01578
    Experimental

    Metrizamide is a solute for density gradient centrifugation offering higher maximum solution density without the problems of increased viscosity. It is also used as a resorbable, non-ionic contrast medium.

  7. Drug

    D-Cysteine

    go.drugbank.com/drugs/DB03201
    Experimental

    A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.

  8. Drug

    Arzoxifene

    go.drugbank.com/drugs/DB06249
    ApprovedWithdrawn

  9. Drug

    Plitidepsin

    go.drugbank.com/drugs/DB04977
    Investigational

    Aplidine is a peptide found in tunicates which shows promise in shrinking tumors in pancreatic, stomach, bladder, and prostate cancers. The specific marine organism is Aplidium albicans. Aplidine is also of interest as a potential treatm...

  10. Drug

    SynOV1.1

    go.drugbank.com/drugs/DB17539
    Investigational

    SynOV1.1 is an investigational cancer immunotherapy developed by SyngenTech. … It is a recombinant oncolytic adenovirus, controlled by synthetic gene circuit, encoding the human immunostimulating factor cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF).